Biopsy Bag Market Size to Hit USD 2.81 Billion by 2033

Biopsy Bag Market Size, Share, Growth Trends, Segmental Analysis: By Material Type (Nylon Biopsy Bags, Polyester Biopsy Bags, Paper Biopsy Bags, Biodegradable Material Bags, Others), By Product Type (Standard Biopsy Bags, Specimen Retrieval Bags Laparoscopic, Endoscopic Biopsy Collection Bags, Pre-labeled and Identification-Integrated Bags, Others), By Application (Laparoscopic and Minimally Invasive Surgery, Endoscopic Procedures, Open Surgical Biopsies, Core Needle and Image-Guided Biopsies, Others), By End User (Hospitals and Surgical Centers, Ambulatory Surgical Centers, Pathology Laboratories, Diagnostic and Research Centers, Others), By Region (North America [United States, Canada, Mexico], Europe [Germany, United Kingdom, France, Italy, Spain, Rest of Europe], Asia-Pacific [China, Japan, India, South Korea, Australia, Rest of Asia-Pacific], Latin America [Brazil, Argentina, Rest of Latin America], Middle East & Africa [UAE, Saudi Arabia, South Africa, Rest of MEA]) and Market Forecast, 2026 – 2033

  • Published: May, 2026
  • Report ID: 401
  • Pages: 160+
  • Format: PDF / Excel.

This report contains the Latest Market Figures, Statistics, and Data.

Get a Sample
logo

Biopsy Bag Market Size to Hit USD 2.81 Billion by 2033

(An Updated Version is Available)

1. Introduction

  • 1.1 Report Overview and Scope

  • 1.2 Market Definition

  • 1.3 Study Assumptions and Limitations

  • 1.4 Research Methodology

  • 1.4.1 Primary Research Approach

  • 1.4.2 Secondary Research Approach

  • 1.4.3 Data Triangulation and Validation

  • 1.5 List of Abbreviations and Acronyms

2. Executive Summary

  • 2.1 Market Snapshot and Key Highlights

  • 2.2 Key Market Findings and Strategic Insights

  • 2.3 Market Attractiveness Analysis by Segment

  • 2.4 Analyst Recommendations

3. Market Overview

  • 3.1 Definition and Introduction to Biopsy Bags

  • 3.2 Market Taxonomy and Scope

  • 3.3 Historical Market Evolution (2021–2025)

  • 3.4 Biopsy Bag Ecosystem Overview

  • 3.4.1 Role in Surgical and Diagnostic Workflows

  • 3.4.2 Specimen Handling, Transport, and Storage Standards

  • 3.4.3 Integration with Laboratory Information Management Systems (LIMS)

  • 3.4.4 RFID-Enabled and Smart Biopsy Bag Ecosystem

  • 3.5 Value Chain Analysis

  • 3.5.1 Raw Material and Polymer Suppliers (Polyethylene, Nylon, PVC, Polypropylene)

  • 3.5.2 Manufacturers and Product Developers

  • 3.5.3 Sterilization Service Providers

  • 3.5.4 Distributors and GPOs (AmerisourceBergen, McKesson, Cardinal Health)

  • 3.5.5 End Users (Hospitals, Diagnostic Labs, ASCs, Research Institutes)

  • 3.6 Regulatory and Policy Framework

  • 3.6.1 U.S. FDA Regulations and CLIA-Certified Laboratory Standards

  • 3.6.2 EU Medical Device Regulation (MDR) and CE Marking

  • 3.6.3 ISO 10993 Biocompatibility Standards for Medical Polymers

  • 3.6.4 OSHA Biosafety and Biohazardous Specimen Handling Guidelines

  • 3.6.5 Asia-Pacific Regulatory Landscape (CDSCO, NMPA, PMDA)

  • 3.7 Macroeconomic Factors Influencing Market Growth

  • 3.7.1 Global Cancer Burden and Rising Biopsy Procedure Volumes

  • 3.7.2 Impact of Healthcare Spending Growth in Emerging Markets

  • 3.7.3 Raw Material Price Volatility (PVC Resin, HDPE, Polypropylene)

  • 3.7.4 Impact of Lab Automation and Digital Pathology on Specimen Handling

4. Market Dynamics

  • 4.1 Key Market Drivers

  • 4.1.1 Rising Cancer Prevalence and Increasing Global Biopsy Procedure Volumes

  • 4.1.2 Stringent Infection Control Protocols and Biosafety Mandates Driving Disposable Adoption

  • 4.1.3 Expansion of Diagnostic Imaging Services Enabling Image-Guided Biopsies

  • 4.1.4 Growth of Ambulatory Surgical Centers (ASCs) and Outpatient Diagnostic Services

  • 4.1.5 Advancements in Material Technology (Biocompatible Polymers, Eco-Certified Materials)

  • 4.1.6 Increasing Demand for Precision Diagnostics and Personalized Medicine

  • 4.1.7 AI-Assisted Pathology and Digital Pathology Driving Specimen Volume Growth

  • 4.2 Market Restraints

  • 4.2.1 Fluctuations in Medical-Grade Polymer Supply and Petrochemical Price Volatility

  • 4.2.2 Stringent Regulatory Approval Timelines for Novel Biopsy Bag Designs

  • 4.2.3 Environmental Concerns Over Single-Use Medical Plastic Waste

  • 4.2.4 Limited Awareness and Adoption in Low-Income Healthcare Settings

  • 4.3 Market Opportunities

  • 4.3.1 Smart Biopsy Bags with Integrated RFID and Sensor Technology

  • 4.3.2 Rising Demand for Personalized Medicine and Precision Diagnostics

  • 4.3.3 Sustainable and Eco-Conscious Biopsy Bag Materials (Biodegradable Polymers, Plant-Based Plastics)

  • 4.3.4 Adapting to the Needs of Liquid Biopsies and Molecular Diagnostics

  • 4.3.5 Expanding Healthcare Infrastructure in Asia-Pacific, Latin America, and MEA

  • 4.3.6 Customized Biopsy Bag Solutions for Specialty Procedures and Organ-Specific Biopsies

  • 4.4 Market Challenges

  • 4.4.1 Managing Medical Waste Disposal Costs (USD 2–20 Per Pound)

  • 4.4.2 Ensuring Compatibility with Automated Laboratory Processing Systems

  • 4.4.3 Addressing Cross-Contamination Risks in High-Volume Specimen Processing Environments

  • 4.4.4 Standardization Gaps Across Biopsy Bag Sizes and Configurations

5. Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers

  • 5.2 Bargaining Power of Buyers (Hospitals, Laboratories, GPOs)

  • 5.3 Threat of New Entrants

  • 5.4 Threat of Substitute Products (Alternative Specimen Containers)

  • 5.5 Intensity of Competitive Rivalry

6. PESTEL Analysis

  • 6.1 Political Factors

  • 6.2 Economic Factors

  • 6.3 Social Factors

  • 6.4 Technological Factors

  • 6.5 Environmental Factors

  • 6.6 Legal Factors

7. Technology and Innovation Landscape

  • 7.1 Smart Biopsy Bags with RFID Tracking and Barcode Integration

  • 7.2 Advanced Polymer Materials: LDPE, HDPE, Nylon, and Bioplastics

  • 7.3 Formalin-Free and Alternative Fixative-Compatible Bag Technologies

  • 7.4 Anti-Leakage and Tamper-Evident Closure Innovations

  • 7.5 Gamma Radiation Sterilization Compatibility (25 kGy Standard)

  • 7.6 Integration with Digital Pathology and AI-Assisted Diagnostic Platforms

  • 7.7 Automation-Compatible Biopsy Bags for Lab Robotics

  • 7.8 Eco-Certified and Biodegradable Polymer Innovations

  • 7.9 Micro-Tissue and Nucleic Acid Preservation Technologies for Liquid Biopsies

8. Market Segmentation Analysis

8.1 By Product Type

  • 8.1.1 Disposable Biopsy Bags

  • 8.1.2 Reusable Biopsy Bags

  • 8.1.3 Standard Biopsy Bags

  • 8.1.4 Customized Biopsy Bags

  • 8.1.5 Others

8.2 By Material Type

  • 8.2.1 Polyethylene (LDPE / HDPE)

  • 8.2.2 Polypropylene

  • 8.2.3 Nylon

  • 8.2.4 PVC

  • 8.2.5 Other Synthetic Polymers

  • 8.2.6 Others (Biodegradable and Plant-Based Materials)

8.3 By Closure Type

  • 8.3.1 Zip Lock

  • 8.3.2 Tie Closure

  • 8.3.3 Adhesive Seal

  • 8.3.4 Snap Lock

  • 8.3.5 Others

8.4 By Application

  • 8.4.1 Tumor Biopsy

  • 8.4.2 Organ Biopsy

  • 8.4.3 Soft Tissue Biopsy

  • 8.4.4 Bone Biopsy

  • 8.4.5 Other Tissue Biopsies (Skin, Lymph Node, Endoscopic)

8.5 By End Use

  • 8.5.1 Hospitals

  • 8.5.2 Diagnostic Laboratories

  • 8.5.3 Ambulatory Surgical Centers (ASCs)

  • 8.5.4 Research Institutes and Academic Medical Centers

  • 8.5.5 Others

9. Regional Market Analysis

9.1 North America

  • 9.1.1 Market Overview, Size, and Growth Outlook

  • 9.1.2 United States

  • 9.1.3 Canada

  • 9.1.4 Mexico

9.2 Europe

  • 9.2.1 Market Overview and Regulatory Environment

  • 9.2.2 Germany

  • 9.2.3 United Kingdom

  • 9.2.4 France

  • 9.2.5 Italy

  • 9.2.6 Spain

  • 9.2.7 Poland

  • 9.2.8 Russia

  • 9.2.9 Rest of Eastern Europe

  • 9.2.10 Rest of Western Europe

9.3 Asia-Pacific

  • 9.3.1 Market Overview and High-Growth Outlook

  • 9.3.2 China

  • 9.3.3 Japan

  • 9.3.4 India

  • 9.3.5 South Korea

  • 9.3.6 Australia and New Zealand

  • 9.3.7 ASEAN Countries

  • 9.3.8 Rest of Asia-Pacific

9.4 Latin America

  • 9.4.1 Market Overview

  • 9.4.2 Brazil

  • 9.4.3 Argentina

  • 9.4.4 Rest of Latin America

9.5 Middle East and Africa (MEA)

  • 9.5.1 Market Overview

  • 9.5.2 Saudi Arabia

  • 9.5.3 United Arab Emirates

  • 9.5.4 South Africa

  • 9.5.5 Rest of Middle East and Africa

10. Competitive Landscape

  • 10.1 Market Concentration and Competitive Overview

  • 10.2 Market Share Analysis of Top Players (2025)

  • 10.3 Competitive Benchmarking Matrix

  • 10.4 Key Strategic Developments

  • 10.4.1 Mergers and Acquisitions (Hologic–Endomagnetics, Cardinal Health–ION, GTCR–PathGroup)

  • 10.4.2 Product Launches and New Portfolio Introductions

  • 10.4.3 Partnerships, Distribution Agreements, and Collaborations

  • 10.4.4 Geographic Expansion and Manufacturing Capacity Investments

  • 10.5 Innovation and R&D Investment Analysis

  • 10.6 Patent Landscape and Intellectual Property Trends

  • 10.7 ESG and Sustainability Practices in Biopsy Bag Manufacturing

  • 10.8 GPO and Hospital Network Procurement Trends

11. Company Profiles

(The final report includes a complete list of companies)

11.1 Thermo Fisher Scientific Inc.

  • 11.1.1 Company Overview

  • 11.1.2 Financial Performance

  • 11.1.3 Product Portfolio

  • 11.1.4 Strategic Initiatives

  • 11.1.5 SWOT Analysis

11.2 Cardinal Health, Inc.

11.3 Medline Industries, LP

11.4 3M Company

11.5 BD (Becton, Dickinson and Company)

11.6 Leica Biosystems Nussloch GmbH (Danaher Corporation)

11.7 Sakura Finetek USA, Inc.

11.8 CellPath Ltd.

11.9 Mortech Manufacturing Company, Inc.

11.10 Simport Scientific Inc.

11.11 Electron Microscopy Sciences (EMS)

11.12 CANCER DIAGNOSTICS Inc.

11.13 Citotest Labware Manufacturing Co., Ltd.

11.14 Saati S.p.A.

11.15 Cook Medical LLC

12. Investment and Opportunity Analysis

  • 12.1 High-Growth Segments and Investment Hotspots

  • 12.2 Venture Capital and Private Equity Activity in Medical Diagnostics

  • 12.3 Government and Institutional Healthcare Research Funding (NCI Budget: USD 7.22 Billion, FY2025)

  • 12.4 M&A Landscape and Strategic Partnership Opportunities

  • 12.5 Strategic Recommendations for Market Stakeholders

13. Impact Analysis

  • 13.1 Impact of Rising Global Cancer Burden on Diagnostic Consumable Volumes

  • 13.2 Impact of AI and Digital Pathology on Specimen Handling Workflows

  • 13.3 Impact of COVID-19 on Biopsy Procedure Volumes and Market Recovery

  • 13.4 Impact of Sustainability Mandates on Single-Use Plastic Medical Devices

  • 13.5 Impact of Lab Automation and LIMS Integration on Smart Biopsy Bag Adoption

14. Appendix

  • 14.1 List of Tables

  • 14.2 List of Figures

  • 14.3 Research Methodology Overview

  • 14.4 Data Sources and References

  • 14.5 Glossary of Key Terms (CLIA, LIMS, RFID, LDPE, HDPE, MDR, ASC, GPO, etc.)

  • 14.6 About the Publisher

15. Disclaimer

Enhance your decision-making capabilities with a 5 Reports-in-1
Bundle deal for - more than 40% off!

Our professional analysts will provide you with immediate assistance.